Asia-Pacific Autoimmune disease diagnostics Market has been estimated at USD 1.4365 billion in 2016 and is projected to reach USD 2.236 billion in 2021 at a CAGR of 11.7% during the forecast period from 2016 to 2021. Autoimmune diseases occur as a result of abnormal immune response of the body against healthy body tissues. This diseases are more prevalent in women. Autoimmune diseases diagnostics are used for detection of the type and stage of autoimmune disease. The autoimmune diseases include type 1 diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), rheumatoid arthritis, inflammatory bowel disease, psoriasis, uveitis and autoimmune thyroid disease.
This market has wide applications in consultation & diagnosis, therapy & monitoring and drug discovery & development areas. Hospitals, clinical diagnostics labs, pharmaceutical industries and CROs are the end users of this market.
Increased incidence of chronic autoimmune diseases, increasing disease awareness and improved laboratory automation are the key driving factors for the market. In addition, rising government initiatives trigger the growth of this market. However, High frequency of false positive results and shortage of skilled technicians also limits the market growth.
Asia-Pacific autoimmune disease diagnostic market is segmented by types i.e. Localized autoimmune disease diagnostics and Systemic Autoimmune disease diagnostics, by test which includes antinuclear antibody test, autoantibody test, complete blood count, comprehensive metabolic panel, C-reactive protein test, erythrocyte sedimentation rate, urinalysis and others. On basis of disease, the market is categorized into type 1 diabetes, Graves’ disease, Hashimotos’s thyroiditis, multiple sclerosis, systemic lupus erythematosus (SLE), rheumatoid arthritis, inflammatory bowel disease, psoriasis, uveitis and autoimmune thyroid disease.
Geographically, Asia-Pacific autoimmune disease diagnostics market has been segmented into India, China, Japan, Australia, New Zealand and South Korea. Asia-Pacific shows a high growth potential because of increasing population of people suffering from autoimmune diseases. The market is expected to grow at the fastest rate due to presence of unmet medical needs, and increasing per capita healthcare expenditure. Asian American women experience Rheumatoid arthritis at a rate higher than the general population. Likewise, lupus is more common in woman of Asian origin as compared to women of other region, propelling the market for autoimmune disease diagnostic market to grow. Improving healthcare infrastructure and patient awareness levels in the emerging markets of India and China drive contribute well to the revenues of Asia-Pacific market.
Many players in this market are trying to expand their product portfolio in order to top the global market. While few companies are entering into the market by acquisitions, top companies are expanding their growth in this market by acquiring other companies. Few companies adopted product innovation and new product launches as its key business strategy to ensure its dominance in this market. Major companies discussed in the report are Roche, Abbott Laboratories, Bayer Healthcare, Biogen, Eli Lilly, Quest Diagnostics and GlaxoSmithKline.
Key Deliverables in the Study